BHCM
SPRY icon

Brevan Howard Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

Brevan Howard Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$374K Buy
+46,558
New +$446K ﹤0.01% 1471
2025
Q4 		– Sell
-67,212
Closed -$675K – 2249
2025
Q3 		$675K Buy
+67,212
New +$965K ﹤0.01% 1123
2024
Q4 		– Sell
-32,921
Closed -$477K – 1404
2024
Q3 		$477K Buy
+32,921
New +$392K ﹤0.01% 692

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Brevan Howard Capital Management's SPRY Position: Q1 2026 in Review

Brevan Howard Capital Management opened a new position in ARS Pharmaceuticals (SPRY) in Q1 2026: 46,558 shares worth $374K. The stake represents ﹤0.01% of the portfolio and ranks #1471 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in SPRY as recently as Q3 2025.

Brevan Howard Capital Management first reported a position in SPRY in Q3 2024 and has held it in 3 quarters since. The position peaked at $675K in Q3 2025. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Brevan Howard Capital Management held 46,558 shares of ARS Pharmaceuticals worth $374K as of Q1 2026.
  • ARS Pharmaceuticals was a new Brevan Howard Capital Management position in Q1 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1471 holding.
  • Brevan Howard Capital Management first reported a position in ARS Pharmaceuticals in Q3 2024 and has held it in 3 quarters since.
  • Brevan Howard Capital Management's ARS Pharmaceuticals position peaked at $675K in Q3 2025.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.